STEYER THOMAS F 4
4 · Kezar Life Sciences, Inc. · Filed Jul 5, 2018
Insider Transaction Report
Form 4
STEYER THOMAS F
Other
Transactions
- Conversion
Common Stock
2018-06-25+210,326→ 210,326 total(indirect: By Trust) - Conversion
Common Stock
2018-06-25+125,927→ 125,927 total(indirect: By Trust) - Conversion
Series A Convertible Preferred Stock
2018-06-25−210,326→ 0 total(indirect: By Trust)→ Common Stock (210,326 underlying) - Conversion
Series B Convertible Preferred Stock
2018-06-25−125,927→ 0 total(indirect: By Trust)→ Common Stock (125,927 underlying)
Footnotes (1)
- [F1]Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering.